Therapeutic effects of γ-irradiation in a primary effusion lymphoma mouse model

Shiraishi,Yoshioki; Gotoh,Kumiko; Towata,Tomomi; Shimasaki,Tatsuya; Suzu,Shinya; Kojima,Akihiro; Okada,Seiji

doi:10.3892/etm_00000014

Therapeutic effects of γ-irradiation in a primary effusion lymphoma mouse model

Authors:
- Yoshioki Shiraishi
- Kumiko Gotoh
- Tomomi Towata
- Tatsuya Shimasaki
- Shinya Suzu
- Akihiro Kojima
- Seiji Okada
View Affiliations

Affiliations: Division of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto 860-0811, Japan
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000014
Pages: 79-84

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary effusion lymphoma (PEL) is a unique and recently identified non-Hodgkin's lymphoma in immuno-compromised individuals. PEL is caused by the Kaposi sarcoma-associated herpes virus/human herpes virus 8 (KSHV/HHV-8) and has a peculiar presentation involving liquid growth in the serous body cavity, chemotherapy resistance and poor prognosis. In search of a new therapeutic modality for PEL, we examined the effect of γ-irradiation on PEL-derived cell lines (BCBL-1, BC-1, and BC-3) in vitro and in vivo. An MTT assay and trypan blue exclusion assay revealed that irradiation significantly suppressed cell proliferation in the PEL cell lines in a dose-dependent manner, and induced apoptosis. The PEL cell lines were relatively radiosensitive compared with other hematological tumor cell lines (Raji, Jurkat, and K562 cells). Inoculation of the BC-3 cell line into the peritoneal cavity of Rag2/Jak3 double-deficient mice led to massive ascites formation, and subcutaneous injection of BCBL-1 led to solid lymphoma formation. Total body irradiation (4 Gy x 2) with bone marrow transplantation resulted in the complete recovery of both types of PEL-inoculated mice. These results suggest that total body irradiation with bone marrow transplantation can be successfully applied for the treatment of chemotherapy-resistant PEL.

View Figures

View References

1.	Nador RG, Cesarman E, Chadburn A, et al: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 88:645–656. 1996.
2.	Chen YB, Rahemtullah A and Hochberg E: Primary effusion lymphoma. Oncologist. 12:569–576. 2007.
3.	Cesarman E, Chang Y, Moore PS, et al: Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 332:1186–1191. 1995.
4.	Lee CK: Evolving role of radiation therapy for hematologic malignancies. Hematol Oncol Clin North Am. 20:471–503. 2006.
5.	Gustavsson A, Osterman B and Cavallin-Stahl E: A systematic overview of radiation therapy effects in non-Hodgkin’s lymphoma. Acta Oncol. 42:605–619. 2003.
6.	Renne R, Zhong W, Herndier B, et al: Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med. 2:342–346. 1996.
7.	Cesarman E, Moore PS, Rao PH, et al: In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi’s sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood. 86:2708–2714. 1995.
8.	Arvanitakis L, Mesri EA, Nador RG, et al: Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood. 88:2648–2654. 1996.
9.	Sellins KS and Cohen JJ: Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol. 139:3199–3206. 1987.
10.	Nicoletti I, Migliorati G, Pagliacci MC, et al: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 139:271–279. 1991.
11.	Shinkai Y, Rathbun G, Lam KP, et al: RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 68:855–867. 1992.
12.	Park SY, Saijo K, Takahashi T, et al: Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity. 3:771–782. 1995.
13.	Attia MA and Weiss DW: Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res. 26:1787–1800. 1966.
14.	Harada H, Suzu S, Ito T, et al: Selective expansion and engraftment of human CD16+ NK cells in NOD/SCID mice. Eur J Immunol. 35:3599–3609. 2005.
15.	Vermes I, Haanen C, Steffens-Nakken H, et al: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 184:39–51. 1995.
16.	Boulanger E, Daniel MT, Agbalika F, et al: Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol. 73:143–148. 2003.
17.	Pauley JL, Panetta JC, Schmidt J, et al: Late-onset delayed excretion of methotrexate. Cancer Chemother Pharmacol. 54:146–152. 2004.
18.	Waddington TW and Aboulafia DM: Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review. AIDS Patient Care STDS. 18:67–73. 2004.
19.	Liu L, Eby MT, Rathore N, et al: The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem. 277:13745–13751. 2002.
20.	Chaudhary PM, Jasmin A, Eby MT, et al: Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene. 18:5738–5746. 1999.
21.	Sun Q, Matta H and Chaudhary PM: The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-kappa B activation. Blood. 101:1956–1961. 2003.
22.	Mayo MW and Baldwin AS: The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 1470:M55–M62. 2000.
23.	Keller SA, Schattner EJ and Cesarman E: Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood. 96:2537–2542. 2000.
24.	Dabaghmanesh N, Matsubara A, Miyake A, et al: Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. Cancer Sci. 100:737–746. 2009.
25.	Keller SA, Hernandez-Hopkins D, Vider J, et al: NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood. 107:3295–3302. 2006.
26.	Takahashi-Makise N, Suzu S, Hiyoshi M, et al: Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway. Int J Cancer. 125:1464–1472. 2009.
27.	McConkey D, Nawrocki ST and Andtbacka R: Velcade displays promising activity in primary effusion lymphoma cells. Cancer Biol Ther. 4:491–492. 2005.
28.	An J, Sun Y, Fisher M, et al: Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia. 18:1699–1704. 2004.
29.	Boulanger E, Meignin V and Oksenhendler E: Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. Br J Haematol. 141:559–561. 2008.
30.	Gospodarowicz M: Radiotherapy in non-Hodgkin lymphomas. Ann Oncol. 19(Suppl 4): iv47–iv50. 2008.
31.	Cassoni A, Ali U, Cave J, et al: Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma. J Clin Oncol. 26:5297–5299. 2008.
32.	Dubray B, Breton C, Delic J, et al: In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin’s lymphomas. Radiother Oncol. 46:185–191. 1998.
33.	Bankert RB, Hess SD and Egilmez NK: SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. Front Biosci. 7:c44–c62. 2002.
34.	Bankert RB, Egilmez NK and Hess SD: Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. 22:386–393. 2001.
35.	Shultz LD, Ishikawa F and Greiner DL: Humanized mice in translational biomedical research. Nat Rev Immunol. 7:118–130. 2007.